D SEED THERAPEUTICS Trademark
Trademark Overview
On Wednesday, August 27, 2025, a trademark application was filed for D SEED THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the D SEED THERAPEUTICS trademark a serial number of 99361665. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, May 28, 2026. This trademark is owned by SEED Therapeutics US, Inc.. The D SEED THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:
Drug discovery and pharmaceutical drug development; Drug validation services, namely, scientifically demonstrating that a new molecular entity has the potential to achieve, or achieves an acceptable balance of benefit to the patients versus side effects; Pharmaceutical research and development; providing medical research and scientific information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, pharmaceutical, clinical research and medical research information about pharmaceutical drug development via the internet; consulting services in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology research, and design, planning, and implementation of clinical trials; research and development of new products; scientific, research and development services; medical research services; Providing information about medical and scientific research relating to the identification of ubiquitin ligases ...
General Information
| Serial Number | 99361665 |
| Word Mark | D SEED THERAPEUTICS |
| Filing Date | Wednesday, August 27, 2025 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, May 28, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, June 16, 2026 |
Trademark Statements
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| NOT AVAILABLE | "THERAPEUTICS" |
| Description of Mark | The mark consists of a shaded hexagon with the letter "D" in the center, and a vertical line above and below the "D" splitting the hexagon in half. Below the design is the stylized wording "SEED" with second "E" facing backwards. Below this Is the smaller stylized wording "THERAPEUTICS". |
| Goods and Services | Drug discovery and pharmaceutical drug development; Drug validation services, namely, scientifically demonstrating that a new molecular entity has the potential to achieve, or achieves an acceptable balance of benefit to the patients versus side effects; Pharmaceutical research and development; providing medical research and scientific information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; providing scientific, pharmaceutical, clinical research and medical research information about pharmaceutical drug development via the internet; consulting services in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology research, and design, planning, and implementation of clinical trials; research and development of new products; scientific, research and development services; medical research services; Providing information about medical and scientific research relating to the identification of ubiquitin ligases for the purposes of degrading a disease-causing protein; scientific consultancy services in the field of identifying ubiquitin ligases for the purposes of degrading a disease-causing protein; Providing information about medical and scientific research with respect to using a photocatalyst molecule for labeling a protein proximate to a target disease-causing protein within a live cell; scientific consultancy services in the field of using a photocatalyst molecule for labeling a protein proximate to a target disease-causing protein within a live cell |
Classification Information
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, August 27, 2025 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | SEED Therapeutics US, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | King of Prussia, PA 19406
US |
Trademark Events
| Event Date | Event Description |
| Wednesday, August 27, 2025 | NEW APPLICATION ENTERED |
| Wednesday, August 27, 2025 | APPLICATION FILING RECEIPT MAILED |
| Friday, January 16, 2026 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, January 16, 2026 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Tuesday, January 20, 2026 | ASSIGNED TO EXAMINER |
| Wednesday, January 21, 2026 | NON-FINAL ACTION WRITTEN |
| Wednesday, January 21, 2026 | NON-FINAL ACTION E-MAILED |
| Wednesday, January 21, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, April 20, 2026 | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Monday, April 20, 2026 | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Friday, April 24, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, April 24, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, April 24, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, May 21, 2026 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, May 21, 2026 | EXAMINERS AMENDMENT E-MAILED |
| Thursday, May 21, 2026 | EXAMINER'S AMENDMENT ENTERED |
| Thursday, May 21, 2026 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Thursday, May 21, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
